A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Male Models, Molecular Protein-Arginine N-Methyltransferases 0303 health sciences Cell Death Dose-Response Relationship, Drug Molecular Structure Antineoplastic Agents Mice, Inbred Strains Lymphoma, Mantle-Cell Crystallography, X-Ray Isoquinolines Methylation Xenograft Model Antitumor Assays 3. Good health Inhibitory Concentration 50 03 medical and health sciences Pyrimidines Cell Line, Tumor Animals Humans Cell Proliferation Protein Binding
DOI: 10.1038/nchembio.1810 Publication Date: 2015-04-27T15:26:20Z
ABSTRACT
Protein arginine methyltransferase-5 (PRMT5) is reported to have a role in diverse cellular processes, including tumorigenesis, and its overexpression is observed in cell lines and primary patient samples derived from lymphomas, particularly mantle cell lymphoma (MCL). Here we describe the identification and characterization of a potent and selective inhibitor of PRMT5 with antiproliferative effects in both in vitro and in vivo models of MCL. EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity in biochemical assays with a half-maximal inhibitory concentration (IC50) of 22 nM and broad selectivity against a panel of other histone methyltransferases. Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death, with IC50 values in the nanomolar range. Oral dosing with EPZ015666 demonstrated dose-dependent antitumor activity in multiple MCL xenograft models. EPZ015666 represents a validated chemical probe for further study of PRMT5 biology and arginine methylation in cancer and other diseases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (479)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....